Frailty and sarcopenia are common complications of cirrhosis. Frailty has been described as an increased susceptibility to stressors secondary to a cumulative decline in physiologic reserve; this decline occurs with aging or is a result of the disease process, across multiple organ systems. Sarcopenia, a key component of frailty, is defined as progressive and generalized loss of skeletal muscle mass and strength. The presence of either of these complications is associated with increased morbidity and mortality, as these are tightly linked to decompensation and increased complication rates. Recognition of these entities is critical. Studies have shown improvement in muscle strength and function lead to reduced mortality, suggesting both frailty and sarcopenia are modifiable risk factors. In this review we outline the prevalence of frailty and sarcopenia in cirrhosis and the impact on clinical outcomes such as decompensation, hospitalization, and mortality. Existing and potential novel therapeutic approaches for frailty and sarcopenia are also reviewed.
T he social and economic burden of cirrhosis is enormous due to complications requiring repeat hospitalizations. 1 Frequent hospitalizations lead to absence from work (for patients and caregivers), decreased quality of life (QOL), and increased morbidity and mortality. Encephalopathy, ascites, and variceal bleeding account for the majority of hospital admissions. 1 Other complications that play a key role in the prognosis of cirrhotic patients include malnutrition, sarcopenia, debility, metabolic, and immune system abnormalities. These complications, whether in isolation or in combination, increase the patient's susceptibility to adverse outcomes, and define frailty. Patients with endstage liver disease (ESLD) are at a higher risk of frailty and have increased risk of mortality secondary to this. 2, 3 Frailty was first described in the geriatric literature, but now has been studied extensively and has been validated in outpatients with cirrhosis. 2 It is described as an increased susceptibility to stressors secondary to a cumulative decline in physiologic reserve. 2 Sarcopenia, a key component of frailty, is defined as progressive and generalized loss of skeletal muscle mass and strength. 4 Sarcopenia, a key component of frailty, is defined as progressive and generalized loss of skeletal muscle mass, strength and function. 4 In addition, sarcopenia is associated with increased mortality. 5 There is an increased prevalence of frailty and sarcopenia in patients with cirrhosis, and this increases with advancing stages of liver disease (see Figure 1) . 5, 6 Frailty and sarcopenia are tightly linked and one cannot be addressed alone adequately. The presence of either is associated with increased morbidity and mortality, 2, 3, 5, 6 as these are tightly linked to decompensation and increased complication rates (see Supplementary  Figure 1) . 2, 7 The presence of both further compounds this risk.
In this review, we outline the prevalence of frailty and sarcopenia in cirrhosis and their impact on clinical outcomes such as decompensation, hospitalization, and mortality.
Assessment of Frailty
A significant proportion of individuals with cirrhosis fulfill the criteria for frailty. Up to 25% of liver transplant candidates were categorized as frail using the Fried frailty instrument (FFI). 2 Liver failure is a driver of this process, as there is significant overlap between the manifestations of frailty and those of synthetic liver dysfunction. Currently, there is no gold standard assessment for frailty. Many indices and measurement tools exist to quantify frailty in cirrhosis (see Table 1 ). Collectively, these tests assess for weight loss, physical stamina, and function. The FFI is commonly used in patients with ESLD awaiting liver transplantation (LT).
Assessment of Sarcopenia
Sarcopenia is found in 40%-60% of patients with ESLD. 5, 8 This range is likely due to absence of a validated definition and lack of objectivity and reproducibility of available tests (see Table 2 ). 9 In the aging population, sarcopenia is defined as loss of muscle mass 2 standard deviations below the normal mean. The European Working Group on Sarcopenia in Older People recommends using both low muscle mass and low muscle function to diagnose sarcopenia. 4 However, most studies of sarcopenia focus on objective measures of muscle mass alone. Many consider skeletal muscle imaging with computed tomography or magnetic resonance imaging to be a gold standard tool. 10 The L3 skeletal muscle index is commonly used, though others claim psoas muscle is sufficient for diagnosis.
5,11
Decompensation and Pre-LT Hospitalization in Frailty Hospitalization in cirrhotic patients portends a poor prognosis independent of the stage of liver disease 1 as it increases the risk of death. 3 In a recent study, where frailty was assessed using gait speed, a 0.1 m/s decrease in gait speed was associated with a significant increase in hospitalization due to cirrhosis-related complications.
7 Patients who had a gait speed of 1 m/s, considered to be normal, had on average 6 hospital days per year compared with 21 hospital days per year and 40 days per year in those with gait speeds of 0.5 m/s and 0.25 m/s, respectively. 7 The most common reason for hospitalization was ascites (30%), followed by HE (25%), infections (13%), and gastrointestinal bleeding (9%). HE also is more prevalent in individuals who are frail, though this was not significant. 2 Patients determined to be frail using the FFI are significantly more likely to have ascites when compared with their counterparts (57% vs 34%; P ¼ .01).
2 This is not surprising, as the presence of ascites increases the risk of protein malnutrition by increasing resting energy expenditure 12 and via reduced oral intake.
Decompensation and Pre-LT Hospitalization in Sarcopenia
Sarcopenia is an independent risk factor for HE 9 and its presence is associated with a higher prevalence of HE in some studies but not in others. 13 
Mortality in Frail Patients
Frailty is a powerful prognostic sign in patients with ESLD and is associated with an increase in waitlist mortality. This relationship is exaggerated in those with a lower Model for End-Stage Liver Disease (MELD) score (<18), indicating the MELD score underestimates mortality in this patient population. 2 An increase in the overall FFI by a single unit was associated with a 45% increased risk in waitlist mortality (P ¼ .01) in 1 study. 2 It is in patients with lower MELD scores that the use of frailty measures may lead to the greatest benefit. The measurement of frailty adds to the prediction of 90-day mortality for hospitalized patients; those with a low independence for activity of daily living score have an odds ratio of 1.83 for mortality. 3 
Mortality in Sarcopenic Patients
Sarcopenia is an independent risk factor for increased waitlist mortality with a 2.4-fold increased risk. 5 This Figure 1 . Sarcopenia in different stages of liver disease. relationship was also more pronounced with lower MELD scores. A static radiographic image may not be reflective of functional muscle status. A simple and safe assessment of functional status in patients with cirrhosis is the 6-minute walk test (6MWT).
14 A 6MWT of <250 m has a sensitivity of 90% for identifying patients with increased risk for mortality pre-LT, with a 52% reduction in mortality for every 100 m improvement in 6MWT. 14 Another measure of functional muscle strength is the hand grip strength, also associated with all-cause mortality. 15 Both the rate and change in function impact waitlist mortality. 16 In 1 study, an increase in hand grip strength of 1 kg led to a decrease in waitlist mortality of 11%. 16 Similarly, an improvement in gait speed of 0.1 m/s led to a 28% decrease in waitlist mortality. 16 These results highlight the importance of diagnosis and intervention for these conditions.
The addition of sarcopenia to the MELD score improves the prediction of 3-month and 6-month survival (c-statistics of 0.85 and 0.80, respectively; compared with c-statistics of 0.82 and 0.77, respectively). 17 This score outperformed the MELD in patients with MELD score <15 and in those with refractory ascites. Similarly, the MELD-psoas score outperformed the MELD score (c-statistic 0.82 compared with 0.80) and was comparable to the MELD sodium score (c-statistic 0.82). 18 
Strategies to Improve Frailty
Presently, there is a lack of intervention studies in frail patients with ESLD. Dietary management has led to beneficial results in frail community dwelling elderly patients where nutritional intervention led to a 2.98 higher odds of reducing frailty. 19 Similarly, 2 randomized controlled trials (RCTs) assessing the impact of exercise in this patient population showed reduction in frailty, improvement in functional scores as measured by FFI and Short Physical Performance Battery, and an improvement in QOL. 19, 20 Clearly more studies in the ESLD population are needed.
Strategies to Improve Sarcopenia
An increase in oral caloric intake and nutritional supplementation can decrease gluconeogenesis leading to increased muscle mass. 8 Protein based calories or branched-chain amino acid supplementation specifically can improve muscle mass and reduce protein catabolism. 21 In 1 study, branched-chain amino acid supplementation led to better survival in sarcopenic patients (P ¼ .02). 21 Further study into leucine-enriched essential amino acids, which are a substrate for protein synthesis, and play a key role in muscle anabolism and autophagy regulation are warranted. Jamar dynamometer used to determine dominant hand grip strength.
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Late evening snacks or frequent snacks (ranging from 200 kcal to 250 kcal) have also led to beneficial results. 22 As fasting has been shown to precipitate protein catabolism quickly in cirrhotic patients these diets aim to reduce fasting time whereby reducing muscle and lipid catabolism. 22 Previous studies have shown exercise to enhance functional capacity in older adults and in those with chronic disease. 19, 20 More studies are needed to assess the safety and impact of exercise in the ESLD population, as it could lead to augmentation of portal pressures. 23 One pilot RCT showed moderate exercise (where patient heart rate was maintained at 60%-70% of maximum) led to a significant increase in muscle mass and a significant improvement in the 6MWT. 24 Myostatin, an inhibitor of protein synthesis and regeneration, is elevated in patients with cirrhosis. 25 Myostatin activates 2 of the major skeletal muscle proteolytic pathways-the ubiquitin-proteasome pathway and autophagy mediated proteolysis. 26 Hyperammonemia can stimulate myostatin expression, whereas testosterone and growth hormone (GH) inhibit it. 26, 27 Up to 90% of men with cirrhosis have low levels of testosterone. 28 Levels of insulin-like growth factor, which is transcribed by the interaction of GH with its receptors, are low, and a relative state of GH resistance is suspected in cirrhosis. 29 Animal studies have shown myostatin antagonists reduce these levels without affecting liver function. 30 One RCT showed the use of humanized myostatin antibody led to a small increase in appendicular lean body mass (in sarcopenic older adults). 31 Similarly, a recent double-blind placebo controlled trial showed a significant improvement in appendicular lean body mass (with intramuscular testosterone injections in cirrhotic men with low testosterone levels). 32 Clearly, further human studies are needed. The use of transjugular intrahepatic portosystemic shunt (TIPS) has been shown to reverse sarcopenia. 33 This is possibly due to a reduction in portal pressures and improved gut motility, absorption, and appetite from reduced ascites. TIPS also leads to increased adiponectin (a positive regulator of insulin and enhances muscle fat oxidation and glucose transport) and an anabolic state. 33 Reduced hepatocyte perfusion and reduced first-pass elimination of adiponectin after TIPS may contribute toward the increased levels. 33 LT is intuitively the ultimate treatment for sarcopenia in this population. However, there is no consensus on the effects of LT on sarcopenia. Montano-Loza et al. 13 reported a reversal of sarcopenia in 28% of the patients over a median time of 43 months after LT. The lack of improvement in 72%, however, needs further evaluation. Two smaller studies showed only 6% of patients had an improvement in sarcopenia post-LT 34 while the other showed 25% of the patients had an improvement. 35 The authors concluded that in the absence of risk factors (immunosuppression use, hospitalization, post-LT complications, renal failure, and disease recurrence), there is improvement in muscle abnormalities following LT. 35 Further studies looking at the course of sarcopenia post-LT and its effects on complications, survival, and QOL are needed.
Conclusions
Frailty and sarcopenia are common in patients with ESLD with increasing prevalence with advancing liver disease and are clearly associated with increased rates of decompensation, hospitalization, and mortality. Recognition of these entities is critical as both sarcopenia and frailty are modifiable risk factors. 14, 16 Whether risk scores incorporating sarcopenia and frailty to the MELD score to address the discrepancy in mortality versus aggressive intervention to improve mortality should be pursued remains to be determined. As organ allocation is already challenged by multiple factors, the best intervention in the current era includes dietary changes including increased oral protein intake, supplementation, or frequent snacks. Exercise appears to be safe, but further studies are needed. Myostatin antagonists and interventions such as TIPS require further study. Sarcopenia and frailty after LT also need further study to improve the disappointing data regarding the effect of LT on improving these comorbidities.
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